Bulk Inquiry
MHY 553
- NSC 33005
- Soluble in DMSO
- MF: C13H9NO2S
- MW: 243.28
Description
MHY553 is an agonist of the nuclear receptor PPARα that promotes transcriptional programs involved in mitochondrial and peroxisomal fatty-acid oxidation. It increases PPARα nuclear signaling while reducing inflammatory and lipogenic responses in hepatic models.
Oral MHY553 treatment reduced age-associated hepatic steatosis in mice, accompanied by increased β-oxidation signaling and decreased inflammatory markers. It is used to investigate PPARα-dependent lipid metabolism, aging-related liver changes and the relationship between fatty-acid oxidation and hepatic inflammation.
Key Features
- PPARα agonist
- Promotes fatty-acid β-oxidation pathways
- Reduces hepatic inflammatory signaling
- Orally bioactive in aging-related steatosis models
Applications
- PPARα nuclear-receptor research
- Hepatic lipid-metabolism studies
- Fatty-acid oxidation assays
- Aging and liver research
- Steatosis and inflammation models
More Information
| Parent CAS No. | 6265-56-1 |
|---|---|
| Chemical Name | 4-(Benzo[d]thiazol-2-yl)benzene-1,3-diol |
| SMILES | C1C=C2N=C(C3C(O)=CC(O)=CC=3)SC2=CC=1 |
| MFCD | N.A. |
| InChi | InChI=1S/C13H9NO2S/c15-8-5-6-9(11(16)7-8)13-14-10-3-1-2-4-12(10)17-13/h1-7,15-16H |
| InChiKey | YQIRLDMXXRINIJ-UHFFFAOYSA-N |
| CID | 95746 |
| Short Description | PPARα agonist |
Related Products
| AXON ID | NAME | FROM PRICE |
|---|---|---|
| 1227 | WY 14643 |
From $55.00 |
| 1237 | GW 7647 |
From $104.50 |
| 1567 | KRP 297 |
From $121.00 |
| 1628 | GSK 3787 |
From $99.00 |
| 1950 | CDDO |
From $88.00 |
| 2019 | INT131 |
From $99.00 |
| 2114 | CP 775146 |
From $121.00 |
| 2262 | GW 9662 |
From $66.00 |
| 2402 | MHY 908 |
From $104.50 |
| 2443 | Rosiglitazone |
From $104.50 |
| 2533 | Hydroxypioglitazone |
From $198.00 |
| 2686 | FH535 |
From $82.50 |
| 2706 | FH535 sodium salt |
From $88.00 |
| 2727 | Elafibranor |
From $99.00 |
| 3999 | Saroglitazar magnesium |
From $176.00 |
| 4430 | Indeglitazar |
From $88.00 |
